Cart
sales@molnova.com
JNJ-?10198409
CAS No. 627518-40-5
JNJ-?10198409( —— )
Catalog No. M24628 CAS No. 627518-40-5
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 84 | In Stock |
|
| 10MG | 124 | In Stock |
|
| 25MG | 210 | In Stock |
|
| 50MG | 303 | In Stock |
|
| 100MG | 433 | In Stock |
|
| 200MG | 607 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ-?10198409
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM).
-
DescriptionJNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
-
In VitroJNJ-10198409 has potent antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM) and is a potent inhibitor of the c-Abl kinase (IC50=22 nM).
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFRβ|PDGFRα
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number627518-40-5
-
Formula Weight325.34
-
Molecular FormulaC18H16FN3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL?(256.13 mM;?Need ultrasonic)
-
SMILESCOC1=C(C=C2C(=C1)CC3=C2NN=C3NC4=CC(=CC=C4)F)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204.
molnova catalog
related products
-
Regorafénib N-oxyde ...
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
-
Rinucumab
Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
-
SU16f
SU16f is a potent and selective PDGFRβ inhibitor (IC50s: 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively).
